Arvinas (ARVN) Stock Forecast, Price & News

Arvinas (NASDAQ:ARVN) Frequently Asked Questions

Is Arvinas a buy right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 2 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arvinas stock.
View analyst ratings for Arvinas or view top-rated stocks.

When is Arvinas' next earnings date?

Arvinas is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Arvinas.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) announced its earnings results on Thursday, May, 5th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.91) by $0.29. The business had revenue of $24.20 million for the quarter, compared to analysts' expectations of $25.51 million. Arvinas had a negative trailing twelve-month return on equity of 29.38% and a negative net margin of 326.72%. The firm's quarterly revenue was up 340.0% on a year-over-year basis.
View Arvinas' earnings history.

What price target have analysts set for ARVN?

19 equities research analysts have issued 12 month price targets for Arvinas' stock. Their forecasts range from $43.00 to $170.00. On average, they expect Arvinas' share price to reach $108.71 in the next year. This suggests a possible upside of 145.0% from the stock's current price.
View analysts' price targets for Arvinas or view top-rated stocks among Wall Street analysts.

Who are Arvinas' key executives?

Arvinas' management team includes the following people:

• Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 62, Pay $1.07M)
• Mr. Sean A. Cassidy CPA, CPA, M.B.A., CFO & Treasurer (Age 52, Pay $667.73k) (LinkedIn Profile)
• Dr. Ian Taylor Ph.D., Chief Scientific Officer (Age 59, Pay $686.8k)
• Dr. Ronald A. Peck, Chief Medical Officer (LinkedIn Profile)
• Mr. Jeff Boyle, VP of Investor Relations
• Mr. Matthew Batters J.D., Gen. Counsel (Age 46)
• Dr. Randy Teel Ph.D., Sr. VP of Corp. & Bus. Devel. (Age 43)
• Mr. Steve Weiss, VP of HR (Age 53)
• Dr. John A. Grosso Ph.D., Sr. VP of R&D Technical Operations (Age 65)
• Ms. Angela M. Cacace Ph.D., Sr. VP of Neuroscience & Platform Biology (Age 54)

Who are some of Arvinas' key competitors?

Some companies that are related to Arvinas include Jazz Pharmaceuticals (JAZZ), Organon & Co. (OGN), Teva Pharmaceutical Industries (TEVA), Grifols (GRFS), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Maravai LifeSciences (MRVI), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Acerus Pharmaceuticals (ASPCF), Ionis Pharmaceuticals (IONS), Intra-Cellular Therapies (ITCI), Ascendis Pharma A/S (ASND), Perrigo (PRGO) and Alkermes (ALKS).
View all of ARVN's competitors.

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.57%), BlackRock Inc. (6.63%), Bellevue Group AG (4.10%), JPMorgan Chase & Co. (3.54%), Gilder Gagnon Howe & Co. LLC (2.56%) and State Street Corp (1.92%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends for Arvinas.

Which institutional investors are selling Arvinas stock?

ARVN stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Ally Bridge Group NY LLC, Emerald Mutual Fund Advisers Trust, Frontier Capital Management Co. LLC, Dimensional Fund Advisors LP, Bellevue Group AG, Candriam Luxembourg S.C.A., and Emerald Advisers LLC. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, and Timothy M Shannon.
View insider buying and selling activity for Arvinas or view top insider-selling stocks.

Which institutional investors are buying Arvinas stock?

ARVN stock was bought by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., Paradigm Biocapital Advisors LP, Wellington Management Group LLP, UBS Group AG, American Century Companies Inc., Invesco Ltd., State Street Corp, and Vanguard Group Inc.. Company insiders that have bought Arvinas stock in the last two years include Liam Ratcliffe, and Timothy M Shannon.
View insider buying and selling activity for Arvinas or or view top insider-buying stocks.

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $44.37.

How much money does Arvinas make?

Arvinas has a market capitalization of $2.36 billion and generates $46.70 million in revenue each year. The company earns $-191 million in net income (profit) each year or ($4.170010) on an earnings per share basis.

How many employees does Arvinas have?

Arvinas employs 280 workers across the globe.

What is Arvinas' official website?

The official website for Arvinas is www.arvinas.com.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at (203) 535-1456 or via email at [email protected].